Calculation of top 10 medicines benchmarks

Each of the top 10 medicines has a benchmark. The benchmark is a percentage uptake value which indicates the minimum proportion of each medicine that is expected to be purchased at the cheaper formulation rate. This can be achieved by either:
  • purchasing a 'biosimilar' version of a drug rather than the more expensive originator version
  • switching to a generic version of a drug rather than a more expensive branded version
Target uptake levels are the minimum uptake level that a trust is expected to achieve over the course of a financial year. It's not always possible to purchase 100% of any medicine at the cheaper rate. Annual uptake targets are derived by taking the total spend on each medicine for the preceding financial year, determining the uptake of biosimilars and calculating the difference between the actual uptake level and the target uptake level.

For switches to generic medicines, we have set simple savings targets for reducing the total spend on a particular product, compared to the brand price. These are also based on spend on each medicine for the preceding financial year.

Targets for the 2021/22 financial year

Medicine Classification Target
Adalimumab
Biosimilar Target saving based on 100% uptake of Best Value Biologic
Trastuzumab
Biosimilar and originator price drop Target uptake level: 90%
Infliximab
Biosimilar Target saving: 90%
Etanercept
Biosimilar Target uptake level: 90%
Rituximab
Biosimilar Target saving: 80%
Bortezomib
Generic Target saving: price drop savings
Azacitidine Generic Target saving: price drop savings  
Posaconazole
Generic Target saving: price drop savings  
Imatinib
Generic Target saving: price drop savings  
Caspofungin
Generic Target saving: price drop savings  



Feedback and Knowledge Base